Abstract
In manufacture of heat labile sterile drug products, the final step involves filtration through sterilizing grade filters. It is the drug manufacturer′s responsibility to check if he has used an integral filter or not. One method used widely to check integrity of a filter is the bubble point test. To confirm that the filter used is integral, post-use integrity test is made obligatory by regulatory bodies. However, Pre-Use/Post-Sterilization Integrity Testing (PUPSIT) of filters remains debatable for the risks associated in its execution. Although PUPSIT is recommended by regulatory bodies, it poses a risk of compromising downstream sterility and involves high costs to mitigate such risks. This study highlights the impact of filter clogging on Bubble Point values with consequent possibility of a non integral filter passing post-use integrity testing. The results clearly show an increase in post-use Bubble Point values, which can camouflage a possible flaw in sterilizing filters. The fluid streams, 20% dextrose, 0.001% Bentonite, Paclitaxel and 0.05% Sodium Hyaluronate were selected, based not only on the commonality of their clogging propensity but also on the different nature of streams that influence the clogging of sterilizing filters. Paclitaxel is an injectable for oncotherapy and 0.05% Sodium Hyaluronate, an ophthalmic. The study was conducted with 0.2 micron sterilizing filters from four different manufacturers. It was observed that some fluid streams show a significant increase in the post-use Bubble Point test values over the pre-use Bubble Point values. This establishes the necessity of performing PUPSIT in certain cases based on the post filtration shift in Bubble Point values. As part of the filter validation studies with specific drug products, additional testing should be carried out to establish the need for PUPSIT on a case by case basis.
- Bubble Point
- PUPSIT
- Post-Use Integrity Testing
- Pre-Use Integrity Testing
- Sterile drug products
- Sterilizing Grade Filters
- Received December 18, 2018.
- Accepted November 6, 2019.
- Copyright © 2019, Parenteral Drug Association
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.